Zinplava

Active Ingredient(s): Bezlotoxumab
FDA Approved: * October 21, 2016
Pharm Company: * MERCK SHARP DOHME
Category: Immune System

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Zinplava Overview

Bezlotoxumab is a human monoclonal antibody designed for the prevention of recurrence of Clostridium difficile infection.[1] Actoxumab and bezlotoxumab are fully human monoclonal antibodies which bind Clostridium difficile (C diff) toxins A and B, respectively. This drug, along with actoxumab, was developed through Phase II efficacy trials by a partnership between Medarex Inc and MassBiologics of the University of Massachusetts Medical School.[2] The project was then licensed to Merck Sharp &...

Read more Zinplava Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Bezlotoxumab

Recent Zinplava Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Bezlotoxumab
  • Injection: 1000ml/40ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zinplava: (1 result)

Sorted by National Drug Code
  • 0006-3025 Zinplava 25 mg/ml Intravenous Injection, Solution by Merck Sharp & Dohme Corp.

Other drugs which contain Bezlotoxumab or a similar ingredient: (1 result)